NICE initially told Eli Lilly that its breast cancer drug Verzenio wasn't cost-effective. So Lilly dished up a price break—and it worked.
Teva has already decided to move its U.S. headquarters, and now it’s planning to move its worldwide headquarters, too.
NICE may have rejected it, but thanks to a new discount, Yescarta's beating archrival Kymriah to adult lymphoma patients on England's health service.
The CAR-T drug is a "step-change" for patients with no other options, but it's too pricey to cover routinely, the cost watchdog said.
NICE said it's "actively engaging" with Biogen to address "uncertainties" about Spinraza's long-term effectiveness.
Vertex CEO Jeffrey Leiden took his fight over CF drug prices to U.K. Prime Minister Theresa May, urging her to step in.
Cost-effectiveness watchdog ICER routinely reviews new drug prices, but now it's aiming to unveil price hikes on older meds.
Sanofi offered a confidential discount as part of a process to secure coverage for Dupixent in the U.K.
Patients in the U.K. won't have access to X-linked hypophosphatemia med Crysvita under a ruling by NICE.